Toulouse, France

Elisabeth Girbal-Neuhauser


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Elisabeth Girbal-Neuhauser: Innovator in Rheumatoid Polyarthritis Diagnosis

Introduction

Elisabeth Girbal-Neuhauser is a prominent inventor based in Toulouse, France. She has made significant contributions to the field of medical diagnostics, particularly in relation to rheumatoid polyarthritis. Her innovative work has led to the development of a unique artificial antigen that plays a crucial role in diagnosing this condition.

Latest Patents

Elisabeth holds a patent for "Antigens derived from filaggrin and their use for diagnosing rheumatoid polyarthritis." This invention focuses on an artificial antigen that is specifically identified by the anti-filaggrin autoantibodies found in the serum of patients suffering from rheumatoid polyarthritis. The antigen consists of a polypeptide that includes all or part of the sequence of one filaggrin unit or a related molecule, where an arginine radical has been substituted by a citrulline radical. This innovation is pivotal for improving diagnostic accuracy in rheumatoid polyarthritis.

Career Highlights

Elisabeth is associated with bioMérieux, Inc., a company renowned for its expertise in in vitro diagnostics. Her work at bioMérieux has allowed her to focus on developing advanced diagnostic tools that enhance patient care and treatment outcomes.

Collaborations

Elisabeth has collaborated with notable colleagues, including Guy Serre and Christian Vincent. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of medical diagnostics.

Conclusion

Elisabeth Girbal-Neuhauser's contributions to the field of rheumatoid polyarthritis diagnosis exemplify her dedication to medical innovation. Her patented work on artificial antigens represents a significant advancement in the diagnostic process, ultimately benefiting patients and healthcare providers alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…